This Version of Afib cda 1.5.1 was added on 14-07-2015 in our apps store. It has been downloaded for free by 162 times by our valuable users. Download Latest Version of Afib cda 1.5.1 for Free. mobile-phones.com.pk is online mobile phone app stock so you come and enjoy unlimited free downloads. Other versions of Afib cda 1.5.1 may also available in our Mobile App store you can search them from related software category.

Make sure that your mobile phone is compatible for this version of Afib cda 1.5.1, Before download Afib cda 1.5.1 Mobile Phone App you should know about the screen resolution, hardware compatibility of your mobile phone device. If you feel this version is right option for your mobile device then go and download Afib cda 1.5.1 for absolutely FREE. You can go to Medical category for large number of related free downloads. In case of any problem for downloading this version please contact us to solve this problem.

Download Latest Version of Afib cda 1.5.1 for Free. Mobile Phones is online mobile phone software stock so you come and enjoy unlimited free downloads.

Mobile phone App store to Download Android Apps , Phone apps, afib cda 1.5.1, Best 3d Android Game dialing software, Entertainment software, Travel Apps, Medical Apss, Multimedia Apps, Utilities Apps for absolutely free. Many more stuff waiting for you e.g skype to chat with your family and friends.

Afib Cda 1.5.1

File Size:

7.64 MB

Downloads:

162

File Type:

Uploaded on:

14-07-2015

Version:

1.5.1

Languages:

EN,DE,SE,ES

Android Support:

Folder:

Medical

DOWNLOAD

Screen Shots:

Description:

The availability of new antithrombotic agents, each with a unique efficacy and bleeding profile, has introduced a considerable amount of clinical uncertainty with physicians. We have developed a clinical decision aid that assists clinicians in determining an optimal antithrombotic regime for the prevention of stroke in patients who are newly diagnosed with non-valvular atrial fibrillation.

This iPad Application allows physicians to accurately and efficiently estimate an individual patient’s baseline annual absolute risk of stroke and bleeding using the CHA2DS2-VASc and HAS-BLED scoring systems.

The Clinical Decision Aid then identifies the antithrombotic agent that is associated with the lowest Net Risk to the patient, and recommends an optimal antithrombotic regime for the prevention of stroke based upon the patient’s particular CHA2DS2VASc and HAS-BLED Scores.